Browse News

Found 78 articles

• Reviva Announces Last Patient Evaluated in Pivotal Phase 3 RECOVER Trial for Brilaroxazine in Schizophrenia

  9/25/2023

  Reviva Pharmaceuticals Holdings, Inc. announced that the last patient in its global pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia has now completed the study.

• Reviva to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

  9/7/2023

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will both present and participate in a conference panel at the H.C. Wainwright 25th Annual Global Investment Conference, taking place September 11-13, 2023 virtually and in New York City, New York.

• Reviva Announces Enrollment Completion for Pivotal Phase 3 RECOVER Study for Brilaroxazine in Schizophrenia

  8/17/2023

  Reviva Pharmaceuticals Holdings, Inc. announced that enrollment is complete in the pivotal Phase 3 RECOVER study evaluating brilaroxazine for schizophrenia, with 402 patients enrolled at multiple sites in the United States, Europe, and Asia.

• Reviva Reports Second Quarter 2023 Financial Results and Recent Business Highlights

  8/14/2023

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) today reported financial results for the second quarter ended June 30, 2023 and summarized recent business highlights.

• Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in August

  7/31/2023

  Reviva Pharmaceuticals Holdings, Inc. today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at two upcoming investor conferences to be held in August 2023.

• Reviva Pharmaceuticals to be Added to Russell Microcap® Index

  6/26/2023

  Reviva Pharmaceuticals Holdings, Inc. announced that the Company will be added to the Russell Microcap® Index, effective after the United States market opens on Monday, June 26, 2023, following the conclusion of the 2023 Russell indexes annual reconstitution.

• Reviva Pharmaceuticals Announces 80% Global Enrollment Update for Pivotal Phase 3 RECOVER Study Evaluating Brilaroxazine for Schizophrenia

  6/22/2023

  Reviva Pharmaceuticals Holdings, Inc. announced over 80% of patients have been enrolled in the pivotal Phase 3 RECOVER study evaluating brilaroxazine for the treatment of schizophrenia.

• Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in June 2023

  6/15/2023

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at two upcoming investor conferences to be held in June 2023.

• Alzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare Conference

  6/13/2023

  Alzamend Neuro, Inc. announced that CEO Stephan Jackman will participate as a panelist at the upcoming Maxim Group Virtual Healthcare Conference, to be held between June 20 –22, 2023.

• Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives

  5/25/2023

  Reviva Pharmaceuticals Holdings, Inc. has presented preclinical data on the novel serotonin-dopamine modulator brilaroxazine in idiopathic pulmonary fibrosis at the 2023 American Thoracic Society International Conference which took place in Washington, DC, USA, May 19-24, 2023.

• Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting

  5/22/2023

  Reviva Pharmaceuticals Holdings, Inc. has presented two posters on promising clinical pharmacology and safety studies data on the novel serotonin-dopamine stabilizer brilaroxazine at the American Society for Pharmacology and Experimental Therapeutics 2023 annual meeting took place in St.

• Reviva Pharmaceuticals Joins Webull Corporate Communications Service Platform

  5/19/2023

  Reviva Pharmaceuticals Holdings, Inc. announced the Company has joined Webull’s Corporate Communications Service Platform.

• Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in May 2023

  5/18/2023

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at two upcoming investor conferences to be held in May 2023.

• Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights

  5/15/2023

  Reviva Pharmaceuticals Holdings, Inc. today reported financial results for the first quarter ended March 31, 2023 and summarized recent business highlights.

• Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

  5/12/2023

  Reviva Pharmaceuticals Holdings, Inc. announced that it will be participating in the Lytham Partners Spring 2023 Investor Conference taking place virtually on Thursday, May 18, 2023.

• Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data

  5/11/2023

  Reviva Pharmaceuticals Holdings, Inc. has presented promising preclinical data on the potential of novel serotonin-dopamine stabilizer brilaroxazine for the treatment of psoriasis at the First International Societies for Investigative Dermatology Meeting in Tokyo, Japan, May 10-13, 2023.

• Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023

  5/4/2023

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting at three upcoming scientific conferences to be held in May 2023.

• Reviva Pharmaceuticals Presented Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives

  5/1/2023

  Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”) has presented the foundational preclinical data that supported the initial clinical development of its novel serotonin-dopamine stabilizer brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry (SOBP) in San Diego.

• Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia

  4/25/2023

  Reviva Pharmaceuticals Holdings, Inc. today announced it will host a KOL webinar on brilaroxazine (RP5063), a serotonin-dopamine modulator in late-stage development for schizophrenia, on May 2 nd at 11:00am ET.

• Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry

  4/20/2023

  Reviva Pharmaceuticals Holdings, Inc. announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will be presenting a poster at the 78th Annual Scientific Convention of the Society of Biological Psychiatry, to be held in San Diego, CA April 27-29, 2023.